Oxford University Press

SHERPA: Yellow

People

  1. Drilon
    Drilon
  2. Motzer
    Motzer
  3. Mellinghoff
    Mellinghoff
  4. Shuman
    Shuman
  5. Rosenblum
    Rosenblum
  6. Dunkel
    Dunkel
  7. Karajannis
    Karajannis
  8. Saltz
    Saltz
  9. Souweidane
    Souweidane
  10. Panageas
    Panageas

Groups

  1. Department of Medicine (1995)
  2. Solid Tumor Oncology Division (1624)
  3. GSK Faculty (765)
  4. Survivorship Research (639)
  5. Population Sciences Research Program (615)
  6. Epidemiology and Biostatistics (465)
  7. Department of Pathology and Laboratory Medicine (415)
  8. Gastrointestinal Oncology Service (386)
  9. Genitourinary Oncology Service (367)
  10. Tow Center for Developmental Oncology (TCDO) (352)
Search Within
Formats
  1. Journal Article (2131)
  2. Meeting Abstract (2072)
  3. Book Section (192)
  4. Review (92)
  5. Editorial (84)
  6. Guidelines (36)
  7. Correspondence (26)
  8. Book Whole (18)
  9. Conference Paper (15)
  10. Research Letter (10)
Groups
  1. Department of Medicine (1995)
  2. Solid Tumor Oncology Division (1624)
  3. GSK Faculty (765)
  4. Survivorship Research (639)
  5. Population Sciences Research Program (615)
  6. Epidemiology and Biostatistics (465)

More Groups

People
  1. Lisa De Angelis (119)
  2. Alexander Drilon (108)
  3. Robert Motzer (96)
  4. Ingo Mellinghoff (93)
  5. Stewart Shuman (88)
  6. Marc Rosenblum (87)

More People

Years
  1. 2025 (129)
  2. 2024 (304)
  3. 2023 (320)
  4. 2022 (331)
  5. 2021 (323)
  6. 2020 (325)

More Years

Publications
  1. Annals of Oncology (1670)
  2. Neuro-Oncology (855)
  3. JNCI: Journal of the National Cancer Institute (492)
  4. Nucleic Acids Research (210)
  5. Clinical Infectious Diseases (140)
  6. American Journal of Clinical Pathology (106)

More Publications

Results (4676)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Efficacy and tolerability of trabectedin in elderly patients with sarcoma: Subgroup analysis from a phase III, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma
    Journal Article

    Jones, R. L.; Demetri, G. D.; Schuetze, S. M.; Milhem, M.; Elias, A.; Van Tine, B. A.; Hamm, J.; McCarthy, S.; Wang, G.; Parekh, T.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Selective RET kinase inhibition for patients with RET-altered cancers
    Journal Article

    Subbiah, V.; Velcheti, V.; Tuch, B. B.; Ebata, K.; Busaidy, N. L.; Cabanillas, M. E.; Wirth, L. J.; Stock, S.; Smith, S.; Lauriault, V.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • 4th ESO-ESMO International Consensus guidelines for advanced breast cancer (ABC 4)
    Journal Article

    Cardoso, F.; Senkus, E.; Costa, A.; Papadopoulos, E.; Aapro, M.; AndreĢ, F.; Harbeck, N.; Aguilar Lopez, B.; Barrios, C. H.; Bergh, J.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Trends in bone marrow sampling and core biopsy specimen adequacy in the United States and Canada: A multicenter study
    Journal Article

    Merzianu, M.; Groman, A.; Hutson, A.; Cotta, C.; Brynes, R. K.; Orazi, A.; Reddy, V.; Teruya-Feldstein, J.; Amre, R.; Balasubramanian, M.; more...
    American Journal of Clinical Pathology (2018)

    Fulltext@MSK | Save
  • Crystal structure and mutational analysis of Mycobacterium smegmatis FenA highlight active site amino acids and three metal ions essential for flap endonuclease and 5' exonuclease activities
    Journal Article

    Uson, M. L.; Carl, A.; Goldgur, Y.; Shuman, S.
    Nucleic Acids Research (2018)

    Fulltext@MSK | Save
  • Overall survival results from a phase III trial of trifluridine/tipiracil versus placebo in patients with metastatic gastric cancer refractory to standard therapies (TAGS)
    Meeting Abstract

    Tabernero, J.; Shitara, K.; Dvorkin, M.; Mansoor, W.; Arkenau, H. T.; Prokharau, A.; Alsina, M.; Ghidini, M.; Faustino, C.; Gorbunova, V.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Efficacy and safety results from IMblaze370, a randomised phase III study comparing atezolizumab + cobimetinib and atezolizumab monotherapy vs regorafenib in chemotherapy-refractory metastatic colorectal cancer
    Meeting Abstract

    Bendell, J.; Ciardiello, F.; Tabernero, J.; Tebbutt, N.; Eng, C.; Di Bartolomeo, M.; Falcone, A.; Fakih, M.; Kozloff, M.; Segal, N.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Activity of larotrectinib in patients with TRK fusion GI malignancies
    Meeting Abstract

    Nathenson, M.; Demetri, G.; Lassen, U.; Hong, D.; Boni, V.; Deeken, J.; Dowlati, A.; Cox, M.; Ku, N.; Cruickshank, S.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • BEACON CRC study safety lead-in: Assessment of the BRAF inhibitor encorafenib plus MEK inhibitor binimetinib plus anti-epidermal growth factor receptor antibody cetuximab for BRAFV600E metastatic colorectal cancer
    Meeting Abstract

    Van Cutsem, E.; Cuyle, P.; Huijberts, S.; Schellens, J.; Elez, E.; Yaeger, R.; Fakih, M.; Montagut, C.; Peeters, M.; Desai, J.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Assessment of tumor response, AFP response, and time to progression in the phase 3 CELESTIAL trial of cabozantinib versus placebo in advanced hepatocellular carcinoma (HCC)
    Meeting Abstract

    Merle, P.; Rimassa, L.; Ryoo, B.; Cicin, I.; Harris, W.; Banu, E.; Sarker, D.; Tan, B.; Van Vlierberghe, H.; Sen, S.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save